Allison Zibelli and Erika Hamilton discussing data from the DESTINY-Breast06 and A-BRAVE trials

Sidney Kimmel Comprehensive Cancer Center at Jefferson shared a post on LinkedIn:

“Dr. Allison Zibelli, Vice Chair of Oncology, Jefferson Methodist Hospital, is joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute to discuss data from the DESTINY-Breast06 and A-BRAVE trials on the American Society of Clinical Oncology (ASCO) Daily News Podcast.

The DESTINY-Breast06 trial is investigating the antibody-drug conjugate trastuzumab in HR+, HER2-low or HER2-ultralow metastatic breast cancer; the A-BRAVE trial is looking at the immune checkpoint inhibitor avelumab in patients with triple-negative breast cancer.”

Listen to the podcast.
Source: Sidney Kimmel Comprehensive Cancer Center at Jefferson/X

Allison Zibelli, MD, is a hematologist-oncologist in Philadelphia, PA, with 28 years of experience. She specializes in breast cancer and is affiliated with Jefferson Methodist Hospital and Thomas Jefferson University Hospital.

Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.